A Case Report of Androgen Receptor Inhibitor Therapy in Recurrent High-grade Serous Ovarian Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2020 Nov 27

PMID 33245722

Citations 2

Authors

Sewanti Limaye

Prashant Kumar

Ramya Pragya

Janani Sambath

Darshana Patil

Ajay Srinivasan

Sachin Apurva

Navin Srivastava

Sanket Patil

Revati Patil

Vineet Datta

Dadasaheb Akolkar

Rajan Datar

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is common gynaecological malignancy and a leading cause of death among women. Despite the advances in treatment strategies, majority of patients present with recurrence after first- or second-line treatment. Targeted therapy that has proven to be effective in other advanced or metastatic solid tumors have also demonstrated its efficacy in ovarian cancer. Recent studies have shown that the androgen receptor (AR) signalling is involved in pathogenicity and progression of cancer. Current observations suggest AR could be a potential target in managing the disease. In this case report we present a patient with high grade serous ovarian cancer (HGSOC) with multiple relapses with excellent disease control on AR inhibition with bicalutamide.

Citing Articles

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.

Lazzari G, Opattova A, Arena S J Exp Clin Cancer Res. 2024; 43(1):146.

PMID: 38750579 PMC: 11094891. DOI: 10.1186/s13046-024-03065-0.

Increased Local Testosterone Levels Alter Human Fallopian Tube mRNA Profile and Signaling.

Russo A, Cain B, Jackson-Bey T, Lopez Carrero A, Miglo J, MacLaughlan S Cancers (Basel). 2023; 15(7).

PMID: 37046723 PMC: 10093055. DOI: 10.3390/cancers15072062.

References

Safarpour D, Pakneshan S, Tavassoli F . Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. Am J Cancer Res. 2014; 4(4):353-68. PMC: 4106653. View

Osguthorpe D, Hagler A . Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry. 2011; 50(19):4105-13. PMC: 3099172. DOI: 10.1021/bi102059z. View

Birkbak N, Kochupurakkal B, Izarzugaza J, Eklund A, Li Y, Liu J . Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013; 8(11):e80023. PMC: 3827141. DOI: 10.1371/journal.pone.0080023. View

Tuna M, Ju Z, Yoshihara K, Amos C, Tanyi J, Mills G . Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer. 2019; 122(3):405-412. PMC: 7000721. DOI: 10.1038/s41416-019-0654-8. View

Fenizia F, Pasquale R, Roma C, Bergantino F, Iannaccone A, Normanno N . Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. Transl Lung Cancer Res. 2018; 7(6):668-677. PMC: 6249618. DOI: 10.21037/tlcr.2018.09.23. View

Mizushima T, Miyamoto H . The Role of Androgen Receptor Signaling in Ovarian Cancer. Cells. 2019; 8(2). PMC: 6406955. DOI: 10.3390/cells8020176. View

Reichert Z, Hussain M . Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer. Cancer J. 2016; 22(5):326-329. DOI: 10.1097/PPO.0000000000000214. View

Morse C, Elvin J, Gay L, Liao J . Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecol Oncol Rep. 2017; 21:78-80. PMC: 5510487. DOI: 10.1016/j.gore.2017.06.013. View

van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H . Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138(3):634-9. DOI: 10.1016/j.ygyno.2015.06.032. View

10.

Vassilomanolakis M, Koumakis G, Barbounis V, Hajichristou H, Tsousis S, Efremidis A . A phase II study of flutamide in ovarian cancer. Oncology. 1997; 54(3):199-202. DOI: 10.1159/000227688. View

11.

de Toledo M, Sarian L, Sallum L, Andrade L, Vassallo J, de Paiva Silva G . Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer. Acta Histochem. 2013; 116(3):440-7. DOI: 10.1016/j.acthis.2013.09.010. View

12.

Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A . The Androgen Receptor in Breast Cancer. Front Endocrinol (Lausanne). 2018; 9:492. PMC: 6122126. DOI: 10.3389/fendo.2018.00492. View

13.

Manning-Geist B, Gordhandas S, Giri D, Iasonos A, Zhou Q, Girshman J . Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecol Oncol. 2021; 164(1):12-17. PMC: 9449573. DOI: 10.1016/j.ygyno.2021.10.087. View

14.

Sheach L, Adeney E, Kucukmetin A, Wilkinson S, Fisher A, Elattar A . Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer. 2009; 101(3):498-503. PMC: 2720237. DOI: 10.1038/sj.bjc.6605153. View

15.

Rahim B, ORegan R . AR Signaling in Breast Cancer. Cancers (Basel). 2017; 9(3). PMC: 5366816. DOI: 10.3390/cancers9030021. View

16.

Voutsadakis I . Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation. J Clin Med. 2016; 5(1). PMC: 4730136. DOI: 10.3390/jcm5010011. View

17.

Tworoger S, Lee I, Buring J, Hankinson S . Plasma androgen concentrations and risk of incident ovarian cancer. Am J Epidemiol. 2007; 167(2):211-8. DOI: 10.1093/aje/kwm278. View

18.

Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D . Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012; 12:553. PMC: 3575289. DOI: 10.1186/1471-2407-12-553. View

19.

Vitale S, Groenendijk F, van Marion R, Beaufort C, Helmijr J, Dubbink H . Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer. Biomolecules. 2020; 10(3). PMC: 7175353. DOI: 10.3390/biom10030415. View

20.

Chiong E, Murphy D, Akaza H, Buchan N, Chung B, Kanesvaran R . Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU Int. 2018; 123(1):22-34. DOI: 10.1111/bju.14489. View